NCT03462719 2026-03-12
GLOW
Janssen Research & Development, LLC
Phase 3 Active not recruiting
Clinical Trials
5 trialsNCT03580928 2026-02-13
AVO
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02427451 2026-01-27
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT02475681 2025-08-27
ElevateTN
Acerta Pharma BV
Phase 3 Active not recruiting
NCT03863184 2025-06-06
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
Phase 2 Active not recruiting